{
"info": {
"nct_id": "NCT00544960",
"official_title": "A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)",
"inclusion_criteria": "* Histologically or cytologically confirmed Stage IIIb with pleural/pericardial effusion or Stage IV non-small cell lung cancer (NSCLC).\n* Progression of disease after one prior systemic chemotherapeutic regimen for locally advanced or metastatic NSCLC. (Systemic therapies given in the adjuvant setting are counted only if the patient relapses within 6 months of the last cycle of therapy.) In addition to the one prior chemotherapeutic regimen, patients may have received erlotinib in any setting.\n* All patients must have measurable disease.\n* No unstable or progressive brain metastases.\n* Patients may have received prior radiation therapy but they must have recovered from all treatment-related toxicities.\n* ECOG performance status 0-1\n* Adequate hematologic function\n* Adequate liver and renal function\n* Ability to swallow oral medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Prior chemotherapy regimen containing docetaxel.\n* Active secondary malignancy.\n* Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.\n* Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically or cytologically confirmed Stage IIIb with pleural/pericardial effusion or Stage IV non-small cell lung cancer (NSCLC).",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "Stage IIIb with pleural/pericardial effusion",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IIIb"
},
{
"requirement_type": "condition",
"expected_value": "pleural/pericardial effusion"
}
]
},
{
"exact_snippets": "Stage IV non-small cell lung cancer (NSCLC)",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IV"
},
{
"requirement_type": "type",
"expected_value": "non-small cell lung cancer (NSCLC)"
}
]
}
]
},
{
"line": "* Progression of disease after one prior systemic chemotherapeutic regimen for locally advanced or metastatic NSCLC. (Systemic therapies given in the adjuvant setting are counted only if the patient relapses within 6 months of the last cycle of therapy.) In addition to the one prior chemotherapeutic regimen, patients may have received erlotinib in any setting.",
"criterions": [
{
"exact_snippets": "Progression of disease after one prior systemic chemotherapeutic regimen",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "after one prior systemic chemotherapeutic regimen"
}
]
},
{
"exact_snippets": "locally advanced or metastatic NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "Systemic therapies given in the adjuvant setting are counted only if the patient relapses within 6 months of the last cycle of therapy",
"criterion": "adjuvant therapy relapse",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 6 months of the last cycle of therapy"
}
]
},
{
"exact_snippets": "patients may have received erlotinib in any setting",
"criterion": "erlotinib treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* All patients must have measurable disease.",
"criterions": [
{
"exact_snippets": "measurable disease",
"criterion": "disease",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": true
}
]
}
]
},
{
"line": "* No unstable or progressive brain metastases.",
"criterions": [
{
"exact_snippets": "No unstable or progressive brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "stability",
"expected_value": [
"stable",
"non-progressive"
]
}
]
}
]
},
{
"line": "* Patients may have received prior radiation therapy but they must have recovered from all treatment-related toxicities.",
"criterions": [
{
"exact_snippets": "Patients may have received prior radiation therapy",
"criterion": "prior radiation therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "they must have recovered from all treatment-related toxicities",
"criterion": "treatment-related toxicities",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "* ECOG performance status 0-1",
"criterions": [
{
"exact_snippets": "ECOG performance status 0-1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Adequate hematologic function",
"criterions": [
{
"exact_snippets": "Adequate hematologic function",
"criterion": "hematologic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate liver and renal function",
"criterions": [
{
"exact_snippets": "Adequate liver ... function",
"criterion": "liver function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate ... renal function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Ability to swallow oral medication",
"criterions": [
{
"exact_snippets": "Ability to swallow oral medication",
"criterion": "ability to swallow oral medication",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Prior chemotherapy regimen containing docetaxel.",
"criterions": [
{
"exact_snippets": "Prior chemotherapy regimen containing docetaxel",
"criterion": "chemotherapy regimen",
"requirements": [
{
"requirement_type": "content",
"expected_value": "docetaxel"
}
]
}
]
},
{
"line": "* Active secondary malignancy.",
"criterions": [
{
"exact_snippets": "Active secondary malignancy",
"criterion": "secondary malignancy",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
}
]
},
{
"line": "* Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.",
"criterions": [
{
"exact_snippets": "serious uncontrolled infection",
"criterion": "infection",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
},
{
"requirement_type": "severity",
"expected_value": "serious"
}
]
},
{
"exact_snippets": "symptomatic congestive heart failure (CHF)",
"criterion": "congestive heart failure (CHF)",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
}
]
},
{
"exact_snippets": "unstable angina pectoris",
"criterion": "angina pectoris",
"requirements": [
{
"requirement_type": "stability",
"expected_value": false
}
]
},
{
"exact_snippets": "cardiac arrhythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "psychiatric illness/social situations that would limit compliance with the study requirements",
"criterion": "psychiatric illness/social situations",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": true
}
]
}
]
},
{
"line": "* Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).",
"criterions": [
{
"exact_snippets": "Failure to recover from toxicities related to prior therapy",
"criterion": "recovery from toxicities related to prior therapy",
"requirements": [
{
"requirement_type": "status",
"expected_value": "failure"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}